India, globally recognized as the “Pharmacy of the World,” supplies 20% of the world’s generic medicines and one-third of its vaccines. Hyderabad, the beating heart of this industry, has earned the title of Pharma Capital of India through its unparalleled contributions to pharmaceutical manufacturing, drug discovery, and global exports.

With a thriving ecosystem of cutting-edge research institutions, a skilled workforce, and strategic government policies, Hyderabad is not only driving India’s pharmaceutical dominance but also positioning itself as the Life Sciences Capital of the World by 2030.

Introduction: Why Hyderabad is Called the Pharma Capital of India

India, often hailed as the “Pharmacy of the World,” accounts for nearly 20% of global generic medicine exports and one-third of global vaccine production. At the heart of this pharmaceutical prowess lies Hyderabad, a city that has solidified its status as the epicenter of pharmaceutical innovation, manufacturing, and exports.

Known as the Pharma Capital of India, Hyderabad combines cutting-edge research, world-class infrastructure, and a skilled workforce to drive the nation’s pharmaceutical industry forward. With its strategic policies and robust ecosystem, the city is poised to become the Life Sciences Capital of the World by 2030.

The History and Growth of Hyderabad’s Pharma Industry

The roots of Hyderabad’s pharmaceutical dominance trace back to the 1970s with the establishment of the Indian Drugs and Pharmaceuticals Limited (IDPL), a public-sector undertaking that laid the foundation for the city’s pharma legacy. Over the decades, Hyderabad attracted private and multinational companies, fueled by investor-friendly policies, affordable land, and a rich talent pool.

Companies like Dr. Reddy’s Laboratories, Aurobindo Pharma, and Hetero Labs have transformed Hyderabad into a global hub for pharmaceutical manufacturing and drug discovery. Today, the city contributes nearly one-third of India’s pharmaceutical production and one-fifth of its pharma exports, according to a recent report.

Genome Valley: India’s Largest Biotechnology Cluster

A cornerstone of Hyderabad’s pharma ecosystem is Genome Valley, India’s largest biotechnology cluster, spanning 2,000 acres. This state-of-the-art hub fosters drug discovery, biotech research, and vaccine development, hosting global giants like Novartis, Dr. Reddy’s, and Bharat Biotech.

With over 200 companies and cutting-edge facilities, Genome Valley drives innovation in biotechnology and pharmaceutical R&D. Its role in developing vaccines, such as Bharat Biotech’s Covaxin, has cemented Hyderabad’s reputation as a global leader in life sciences.

Hyderabad’s Role During the COVID-19 Pandemic

Hyderabad emerged as a global lifeline during the COVID-19 pandemic, producing millions of vaccine doses for India and the world. Companies like Bharat Biotech, with its indigenous Covaxin, and Biological E., a key player in vaccine manufacturing, played pivotal roles in the global vaccine supply chain.

Hyderabad’s contribution accounted for one-third of the world’s vaccine output, reinforcing its status as the Vaccine Capital of the World. The city’s robust pharma manufacturing infrastructure and rapid response capabilities were instrumental in addressing global healthcare demands.

Research, Talent, and Infrastructure Supporting Hyderabad’s Pharma Ecosystem

Hyderabad’s pharmaceutical success is underpinned by its world-class research institutions, such as the Centre for Cellular and Molecular Biology (CCMB), Indian Institute of Chemical Technology (IICT), and National Institute of Pharmaceutical Education and Research (NIPER).

These institutions drive innovation in drug development and biotechnology research. The city’s skilled workforce, nurtured by top-tier universities and training programs, ensures a steady pipeline of talent for the industry.

Hyderabad’s logistics infrastructure, including GMR Hyderabad International Airport, facilitates 72% of the city’s high-value pharmaceutical exports to markets like the United States and Europe.

Economic Impact of the Pharmaceutical Industry in Hyderabad and Telangana

Hyderabad’s pharmaceutical industry significantly contributes to India’s economy, accounting for 40% of the country’s bulk drug and formulation exports. The sector has created thousands of jobs, with recent investments of over ₹5,500 crore from 11 pharmaceutical companies expected to generate 9,800 new jobs in the Green Pharma City project.

Telangana’s investor-friendly Life Sciences Policy and initiatives like the Telangana Industrial Health Policy have further boosted the sector’s growth. The state’s vision to become the Life Sciences Capital of the World by 2030 is supported by its thriving ecosystem valued at $80 billion.

Economic Impact of Hyderabad’s Pharmaceutical Industry

Contribution to Exports

• Accounts for 40% of India’s bulk drug and formulation exports
• One-fifth of India’s total pharmaceutical exports originate from Hyderabad
• 72% of Hyderabad’s exports are high-value pharmaceutical shipments to the US and Europe

Employment Generation

• Recent MoUs with 11 pharma companies to create 9,800 jobs
• Investments of ₹5,500 crore in Green Pharma City to boost employment
• Over 1,000 life sciences companies employ thousands in Telangana

Government Support

• Telangana’s Life Sciences Policy offers subsidies and fast-track approvals
• Hyderabad Pharma City project to attract $8.4 billion in investments
• Vision to position Hyderabad as the Life Sciences Capital of the World by 2030

Future Outlook: Pharma City and Beyond

The proposed Green Pharma City, a 19,000-acre integrated industrial park, is set to redefine Hyderabad’s pharmaceutical landscape. Designed to house eco-friendly pharma manufacturing units, the project has attracted investments from major players like Dr. Reddy’s Laboratories, Aurobindo Pharma, and Laurus Labs.

Expected to create 5.6 lakh jobs and attract $8.4 billion in investments, Green Pharma City will enhance Hyderabad’s capacity for pharmaceutical innovation and global exports. The project aligns with Telangana’s vision to build a sustainable, world-class pharma ecosystem.

India’s Pharmaceutical Industry in Context

India is the world’s largest supplier of generic medicines, with a market size projected to reach $130 billion by 2030. The country accounts for 20% of global generic drug exports and one-third of vaccine production.

Hyderabad leads among India’s pharma hubs, outpacing cities like Mumbai, Bengaluru, Pune, and Gujarat. While Mumbai excels in corporate headquarters and Bengaluru in biotech innovation, Hyderabad’s strength lies in its integrated ecosystem of manufacturing, R&D, and exports.

Key Challenges and Opportunities in Indian Pharma

The Indian pharmaceutical industry faces challenges like increasing R&D costs and regulatory compliance but is poised for growth through opportunities such as:

• R&D Investments: Companies like Sai Life Sciences are expanding R&D capabilities in Hyderabad to drive innovation.
• E-Pharmacy Growth: The rise of e-pharmacy platforms is transforming healthcare delivery, with Hyderabad at the forefront.
• Patent Expiries: Opportunities for generic drugs as blockbuster drugs lose patent protection.
• Government Support: Incentives like the Production Linked Incentive (PLI) Scheme bolster pharma manufacturing and exports.

Conclusion: Hyderabad’s Continuing Leadership in India’s Pharma Sector

Hyderabad’s rise as the Pharma Capital of India is driven by its robust ecosystem, strategic investments, and global partnerships. With Genome Valley, world-class research institutions, and the upcoming Green Pharma City, the city is well-positioned to lead India’s vision of becoming a global pharmaceutical powerhouse.

As Hyderabad continues to innovate and expand, it will play a pivotal role in shaping the future of healthcare worldwide.

For more insights on Hyderabad’s pharma industry, visit BioAsia and PharmaTech Summit.

FAQs